المؤلفون: Dosta P; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. pdostapons@bwh.harvard.edu.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. pdostapons@bwh.harvard.edu.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. pdostapons@bwh.harvard.edu., Cryer AM; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Dion MZ; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, USA., Shiraishi T; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Langston SP; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Lok D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Wang J; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Harrison S; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Hatten T; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Ganno ML; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Appleman VA; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Taboada GM; Biodevek, Cambridge, MA, USA., Puigmal N; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Ferber S; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Kalash S; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Prado M; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Rodríguez AL; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Kamoun WS; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Abu-Yousif AO; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Artzi N; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. nartzi@bwh.harvard.edu.; Department of Medicine, Division of Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. nartzi@bwh.harvard.edu.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. nartzi@bwh.harvard.edu.

المصدر: Nature nanotechnology [Nat Nanotechnol] 2023 Nov; Vol. 18 (11), pp. 1351-1363. Date of Electronic Publication: 2023 Jul 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101283273 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1748-3395 (Electronic) Linking ISSN: 17483387 NLM ISO Abbreviation: Nat Nanotechnol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Melanoma* , Nanoparticles*/therapeutic use , Nanoparticles*/chemistry, Animals ; Mice ; Polymers/pharmacology ; Signal Transduction

المؤلفون: Menezes B; Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA., Khera E; Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA., Calopiz M; Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA., Smith MD; Takeda Development Center Americas-Inc. TDCA, Oncology, Lexington, Massachussetts, USA., Ganno ML; Takeda Development Center Americas-Inc. TDCA, Oncology, Lexington, Massachussetts, USA., Cilliers C; Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA., Abu-Yousif AO; Takeda Development Center Americas-Inc. TDCA, Oncology, Lexington, Massachussetts, USA., Linderman JJ; Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA.; Department of Biomedical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA., Thurber GM; Department of Chemical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA. gthurber@umich.edu.; Department of Biomedical Engineering, University of Michigan, 2800 Plymouth Rd, Ann Arbor, Michigan, 48109, USA. gthurber@umich.edu.

المصدر: The AAPS journal [AAPS J] 2022 Oct 07; Vol. 24 (6), pp. 107. Date of Electronic Publication: 2022 Oct 07.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Immunoconjugates*/pharmacokinetics , Neoplasms*/drug therapy, Animals ; Antibodies ; Bystander Effect ; Cell Line, Tumor ; Humans ; Mice

المؤلفون: Knelson EH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ivanova EV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tarannum M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Campisi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Ozgenc I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Noureddine M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Meisenheimer B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Chen M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Piel B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Spicer N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Obua B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Messier CM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Shannon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Graduate Medical Sciences Program, Boston University School of Medicine, Boston, Massachusetts., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Tani T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schol PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lee-Hassett AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zlota A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Vo HV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ha M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Han S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Thai TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gustafson CE; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Venugopal K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Haggerty TJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Albertson TP; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Hartley AV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Eser PO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li ZH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Cañadas I; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Vivero M; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., De Rienzo A; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Richards WG; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Abu-Yousif AO; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Appleman VA; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Gregory RC; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Parent A; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Lineberry N; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Smith EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Miret JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bueno R; Deparment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Cancer immunology research [Cancer Immunol Res] 2022 Aug 03; Vol. 10 (8), pp. 947-961.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy, Adoptive* , Killer Cells, Natural* , Membrane Proteins*/agonists , Mesothelioma, Malignant*, Cell Line, Tumor ; Cell- and Tissue-Based Therapy ; Humans ; Receptors, Chimeric Antigen

المؤلفون: Carideo Cunniff E; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Sato Y; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Mai D; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Appleman VA; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Iwasaki S; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan., Kolev V; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Matsuda A; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan., Shi J; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Mochizuki M; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan., Yoshikawa M; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan., Huang J; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Shen L; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Haridas S; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Shinde V; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Gemski C; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Roberts ER; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Ghasemi O; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Bazzazi H; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Menon S; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Traore T; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Shi P; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Thelen TD; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Conlon J; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Abu-Yousif AO; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Arendt C; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Shaw MH; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts., Okaniwa M; Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts.

المصدر: Cancer research communications [Cancer Res Commun] 2022 Jun 23; Vol. 2 (6), pp. 489-502. Date of Electronic Publication: 2022 Jun 23 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun

مواضيع طبية MeSH: Immunity, Innate* , Neoplasms*/drug therapy, Animals ; Humans ; Mice ; Cytokines ; Interferons ; Signal Transduction ; Tumor Microenvironment ; Clinical Trials, Phase I as Topic

المؤلفون: Vyskocil S, Cardin D, Ciavarri J, Conlon J, Cullis C, England D, Gershman R, Gigstad K, Gipson K, Gould A, Greenspan P, Griffin R, Gulavita N, Harrison S, Hu Z, Hu Y, Hata A, Huang J, Huang SC, Janowick D, Jones M, Kolev V, Langston SP, Lee HM, Li G, Lok D, Ma L, Mai D, Malley J, Matsuda A, Mizutani H, Mizutani M, Molchanova N, Nunes E, Pusalkar S, Renou C, Rowland S, Sato Y, Shaw M, Shen L, Shi Z, Skene R; Drug Discovery Sciences, Takeda Pharmaceuticals International Company, 9625 Towne Centre Drive, San Diego, California 92121, United States., Soucy F, Stroud S, Xu H, Xu T, Abu-Yousif AO, Zhang J

المصدر: Journal of medicinal chemistry [J Med Chem] 2021 May 27; Vol. 64 (10), pp. 6902-6923. Date of Electronic Publication: 2021 May 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Membrane Proteins/*agonists , Nucleotides, Cyclic/*chemistry , Pyrimidines/*chemistry, Administration, Intravenous ; Animals ; Binding Sites ; Cell Line, Tumor ; Half-Life ; Humans ; Immunotherapy ; Membrane Proteins/metabolism ; Mice ; Molecular Docking Simulation ; Neoplasms/pathology ; Neoplasms/therapy ; Nucleotides, Cyclic/metabolism ; Nucleotides, Cyclic/therapeutic use ; Phosphates/chemistry ; Rats ; Structure-Activity Relationship ; Transplantation, Heterologous

المؤلفون: Khera E; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Cilliers C; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Smith MD; Millennium Pharmaceuticals Inc.(#), Cambridge, MA, USA., Ganno ML; Millennium Pharmaceuticals Inc.(#), Cambridge, MA, USA., Lai KC; Immunogen Inc., Waltham, MA, USA., Keating TA; Immunogen Inc., Waltham, MA, USA., Kopp A; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Nessler I; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA., Abu-Yousif AO; Millennium Pharmaceuticals Inc.(#), Cambridge, MA, USA., Thurber GM; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. Electronic address: gthurber@umich.edu.

المصدر: Neoplasia (New York, N.Y.) [Neoplasia] 2021 Feb; Vol. 23 (2), pp. 210-221. Date of Electronic Publication: 2020 Dec 29.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*pharmacokinetics , Bystander Effect/*drug effects , Immunoconjugates/*pharmacokinetics, Animals ; Biomarkers ; Cell Line, Tumor ; Disease Models, Animal ; Drug Monitoring/methods ; Female ; Fluorescent Antibody Technique ; Humans ; Immunoglobulin Fc Fragments/metabolism ; Mice ; Mice, Transgenic ; Tumor Microenvironment/drug effects ; Xenograft Model Antitumor Assays

المؤلفون: Abu-Yousif AO; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts. Adnan.Abu-Yousif@Takeda.com., Cvet D; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Gallery M; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Bannerman BM; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Ganno ML; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Smith MD; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Lai KC; ImmunoGen, Inc. Waltham, Massachusetts., Keating TA; ImmunoGen, Inc. Waltham, Massachusetts., Stringer B; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Kamali A; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Eng K; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Koseoglu S; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Zhu A, Xia CQ; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Landen MS; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Borland M; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Robertson R; Quanta Imaging, Boston, Massachusetts., Bolleddula J; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Qian MG; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Fretland J; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts., Veiby OP; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachsetts.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Oct; Vol. 19 (10), pp. 2079-2088. Date of Electronic Publication: 2020 Aug 11.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Immunoconjugates/*therapeutic use, Animals ; Female ; HEK293 Cells ; Humans ; Immunoconjugates/pharmacology ; Mice ; Mice, Nude ; Tissue Distribution ; Xenograft Model Antitumor Assays

المؤلفون: Nessler I; Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan., Khera E; Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan., Vance S; Crescendo Biologics, Cambridge, United Kingdom., Kopp A; Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan., Qiu Q; ImmunoGen, Waltham, Massachusetts., Keating TA; ImmunoGen, Waltham, Massachusetts., Abu-Yousif AO; Takeda Pharmaceuticals, Cambridge, Massachusetts., Sandal T; Crescendo Biologics, Cambridge, United Kingdom., Legg J; Crescendo Biologics, Cambridge, United Kingdom., Thompson L; Crescendo Biologics, Cambridge, United Kingdom., Goodwin N; Crescendo Biologics, Cambridge, United Kingdom., Thurber GM; Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan. gthurber@umich.edu.; Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.

المصدر: Cancer research [Cancer Res] 2020 Mar 15; Vol. 80 (6), pp. 1268-1278. Date of Electronic Publication: 2020 Jan 15.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Antineoplastic Agents, Alkylating/*pharmacology , Immunoconjugates/*pharmacokinetics , Prostatic Neoplasms/*drug therapy , Single-Domain Antibodies/*pharmacology, Animals ; Antineoplastic Agents, Alkylating/chemistry ; Antineoplastic Agents, Alkylating/therapeutic use ; Cell Line, Tumor ; Computer Simulation ; Female ; Humans ; Immunoconjugates/chemistry ; Immunoconjugates/therapeutic use ; Male ; Mice ; Microscopy, Confocal ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Single-Domain Antibodies/chemistry ; Single-Domain Antibodies/therapeutic use ; Spheroids, Cellular ; Structure-Activity Relationship ; Tissue Distribution ; Xenograft Model Antitumor Assays

المؤلفون: Casaletto JB; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Geddie ML; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Abu-Yousif AO; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Masson K; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Fulgham A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Boudot A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Maiwald T; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Kearns JD; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Kohli N; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Su S; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Razlog M; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Raue A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139; araue@merrimack.com gavin.macbeath@gmail.com., Kalra A; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Håkansson M; SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden., Logan DT; SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden., Welin M; SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden., Chattopadhyay S; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Harms BD; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Nielsen UB; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Schoeberl B; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., Lugovskoy AA; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139., MacBeath G; Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139; araue@merrimack.com gavin.macbeath@gmail.com.

المصدر: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2019 Apr 09; Vol. 116 (15), pp. 7533-7542. Date of Electronic Publication: 2019 Mar 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific/*pharmacology , Antineoplastic Agents, Immunological/*pharmacology , Epithelial Cell Adhesion Molecule/*antagonists & inhibitors , Hepatocyte Growth Factor/*metabolism , Neoplasms, Experimental/*drug therapy , Proto-Oncogene Proteins c-met/*antagonists & inhibitors , Signal Transduction/*drug effects, Animals ; Cell Line, Tumor ; Epithelial Cell Adhesion Molecule/metabolism ; Humans ; Mice ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Proto-Oncogene Proteins c-met/metabolism ; Xenograft Model Antitumor Assays

المؤلفون: Sugimoto H, Ghosh D, Chen S, Smith MD, Abu-Yousif AO, Qian MG

المصدر: Analytical chemistry [Anal Chem] 2018 Nov 20; Vol. 90 (22), pp. 13564-13571. Date of Electronic Publication: 2018 Nov 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6882 (Electronic) Linking ISSN: 00032700 NLM ISO Abbreviation: Anal Chem Subsets: MEDLINE

مواضيع طبية MeSH: Chromatography, Liquid/*methods , Mass Spectrometry/*methods , Neoplasms/*metabolism, Animals ; Cell Membrane/metabolism ; Heterografts ; Humans ; Mice ; Reproducibility of Results